CN103705754B - A kind of Chinese medicine composition of systemic lupus erythematosus - Google Patents
A kind of Chinese medicine composition of systemic lupus erythematosus Download PDFInfo
- Publication number
- CN103705754B CN103705754B CN201410000841.2A CN201410000841A CN103705754B CN 103705754 B CN103705754 B CN 103705754B CN 201410000841 A CN201410000841 A CN 201410000841A CN 103705754 B CN103705754 B CN 103705754B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- sle
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000000596 systemic lupus erythematosus Diseases 0.000 title claims abstract description 73
- 239000003814 drug Substances 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 241000756943 Codonopsis Species 0.000 claims description 8
- 241000628997 Flos Species 0.000 claims description 8
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 14
- 230000007812 deficiency Effects 0.000 abstract description 2
- 230000000116 mitigating effect Effects 0.000 abstract description 2
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 22
- 238000012360 testing method Methods 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 13
- 210000002700 urine Anatomy 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000000630 rising effect Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000003390 Chinese drug Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 108700031361 Brachyury Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002324 prednisone group Chemical group 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- -1 sublimed preparation Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000003805 vibration mixing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Abstract
The invention belongs to medical art, relate to a kind of Chinese medicine composition of systemic lupus erythematosus.In order to make up the deficiencies in the prior art, the misery of mitigation system patients with SLE, this medicine of Chinese medicine composition that the invention provides a kind of systemic lupus erythematosus has significant regulatory T-cell subgroup activity, it is evident in efficacy, safe and reliable, has wide potential applicability in clinical practice.
Description
Technical field
The invention belongs to medical art, relate to a kind of Chinese medicine composition and medical usage thereof of systemic lupus erythematosus.
Background technology
Systemic lupus erythematosus (sle) (systemiclupuserythematosus, SLE) be a kind of diffusivity, systemic autoimmune diseases, mainly involve mucocutaneous, skeletal muscle, kidney and central nervous system, also lung may be involved simultaneously, heart, multiple organ such as blood and system, show various clinical symptoms, its cause of disease and pathogeny are still not clear, multiple autoantibody and crucial immunological abnormality can be detected in Serum in Patients with SLE, lymphocyte function exception and cytokine profiles secretion is unbalance plays an important role in the developing of this disease, CD3+CD4+T cell in research authentication system lupus erythematosus disease human peripheral is had to decline, CD3+CD8+T rises, IL-10 level raises, wherein IL-10 receives much attention in SLE pathogenesis as the representative of Th type cytokines.Interleukin is the polypeptide class of the non-homogeneous adjustment Growth of Cells of a large class, differentiation, mediation signal transmission, and IL-10 is more concerned in systemic lupus erythematosus (sle) research.IL-10 is a pleiotropic cytokines, and have immunostimulation and immunosuppressant dual function, its immunostimulation mainly improves the survival rate of B cell, promotes the secretion of the expression of the propagation of B cell, MHC-class Ⅱ antigens and antibody.There are some researches show that IL-10 can produce Anti-hCG action by stimulating system patients with SLE PBMCs, no matter Patients with SLE is in active stage or catabasis, and in its body, IL-l0 level is all the time higher than normal person.
Systemic lupus erythematosus (sle) there is no radical cure way at present, the long-term even life-long therapy of a lot of needs of patients.Doctor trained in Western medicine controls the therapy of systemic lupus erythematosus (sle) many employings hormone, hormone is controlled systemic lupus erythematosus (sle) and is had distinguished curative effect, but hormone has sizable side effect, and use hormones a large amount of is for a long time unfavorable for the physical and mental health of patient, moreover, subtracting of hormone stops very likely causing aggravation.The way of middle treatment systemic lupus erythematosus (sle) many employings Chinese drugs dispensing, though Chinese drugs dispensing controls systemic lupus erythematosus (sle) have distinguished curative effect, but curative effect only rests on relief of symptoms side, be difficult to fundamentally treat systemic lupus erythematosus (sle), middle treatment systemic lupus erythematosus (sle) is a long-term process, just sees curative effect after generally adhering to treating half a year.Therefore, all there is certain limitation in the Therapeutic Method of current systemic lupus erythematosus (sle).Find a kind of new active drug to carry out systemic lupus erythematosus patient and have very important meaning.
Summary of the invention
In order to make up the deficiencies in the prior art, the misery of mitigation system patients with SLE, the invention provides a kind of Chinese medicine composition of systemic lupus erythematosus, it is evident in efficacy, safe and reliable, has wide potential applicability in clinical practice.
Technical scheme of the present invention is:
A Chinese medicine composition for systemic lupus erythematosus, this Chinese medicine composition is made up of the raw material of following weight portion: Herba Artemisiae Annuae 10-12 part, Cortex Moutan 5-8 part, Herba Epimedii 6-9 part, Herba Dendrobii 3-5 part, Radix Achyranthis Bidentatae 10-12 part, Plumula Nelumbinis 10-12 part, Caulis Spatholobi 3-5 part, Pericarpium Citri Reticulatae 3-5 part, Radix Salviae Miltiorrhizae 10-12 part, Flos Lonicerae 8-10 part, Radix Paeoniae Rubra 6-9 part, Poria 10-12 part, Rhizoma Pinelliae 10-12 part, Radix Codonopsis 10-12 part, Semen Plantaginis 12-15 part, Radix Scrophulariae 9-12 part.
In Chinese medicine composition described above, Radix Glycyrrhizae 5-8 part and Fructus Ligustri Lucidi 12-15 part can also be contained.These two kinds of Chinese medicines can strengthen the therapeutic effect of the above-mentioned Chinese medicine composition of the present invention further.
The present invention also asks to protect above-mentioned Chinese medicine composition preparing the purposes in medicament for treating systemic lupus erythematosus.Test examples 7 of the present invention shows, and in the test of t lymphocyte subset cluster analysis, compared with SLE model group, the CD3+CD4+T cell that the present invention can make SLE sample mice decline rises, and the CD3+CD8+T of rising is declined, and corrects the imbalance state of T cell subgroup; In serum IL-10, the test of anti-ds-DNA antibody assay, compared with SLE model group, the present invention significantly can reduce the rising of SLE mice serum IL-10 and anti-ds-DNA antibody level, wherein dosage group and Normal group there was no significant difference in Chinese medicine composition, illustrates that medicine of the present invention is remarkable for SLE mice therapeutic effect; In the determination test of microdose urine protein, SLE model group albumin content obviously raises, reflection SLE mouse kidney has damage, the present invention significantly can reduce albuminous content in SLE mice urine, Chinese medicine composition low, middle dosage group effect is particularly remarkable, be better than positive drug, and low, the middle dosage group of Chinese medicine composition and Normal group there was no significant difference, show that medicine of the present invention has outstanding therapeutic effect for the damage of SLE mouse kidney.
In order to express Chinese medicine composition of the present invention better, Chinese medicine composition of the present invention can be prepared into dosage form conventional clinically.Such as, the preparations such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule, described pharmaceutical preparation all can prepare according to Chinese medicine preparation preparation method well-known to those skilled in the art.Preferably, Chinese medicine composition of the present invention conveniently preparation technology be prepared into powder, water preparation, tablet or capsule.
Present invention also offers a kind of preparation method of Chinese medicine composition described above, it mainly comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, the alcoholic solution that volumetric concentration is 40%-95% is doubly added according to the 4-9 of coarse powder gross weight, reflux, extract, three times, return time is 2-5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
Chinese medicine composition of the present invention, in systemic lupus erythematosus, compared with prior art has following advantage:
1) compared with the chemotherapeutic agent of Current therapeutic, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, and untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, and improves the quality of life of patient.
2) multi-medicament component is contained in Chinese medicine composition of the present invention, action target spot is numerous, pharmacological evaluation shows it and existing Therapy for Systemic Lupus Erythematosus medicine has significant synergism in treatment, and can significantly reduce systemic lupus erythematosus disease, improve the compliance of patient.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but those skilled in the art should know, described embodiment does not also limit the present invention in any way.
One) example of formulations part
Embodiment 1 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Artemisiae Annuae 10 parts, Cortex Moutan 5 parts, Herba Epimedii 6 parts, Herba Dendrobii 3 parts, Radix Achyranthis Bidentatae 10 parts, Plumula Nelumbinis 10 parts, Caulis Spatholobi 3 parts, Pericarpium Citri Reticulatae 3 parts, Radix Salviae Miltiorrhizae 10 parts, Flos Lonicerae 8 parts, Radix Paeoniae Rubra 6 parts, 10 parts, Poria, the Rhizoma Pinelliae 10 parts, Radix Codonopsis 10 parts, Semen Plantaginis 12 parts, Radix Scrophulariae 9 parts.
Get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, doubly add according to the 4-9 of coarse powder gross weight the alcoholic solution that volumetric concentration is 40%-95%, reflux, extract, three times, return time is 2-5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
Embodiment 2 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Artemisiae Annuae 12 parts, Cortex Moutan 8 parts, Herba Epimedii 9 parts, Herba Dendrobii 5 parts, Radix Achyranthis Bidentatae 12 parts, Plumula Nelumbinis 12 parts, Caulis Spatholobi 5 parts, Pericarpium Citri Reticulatae 5 parts, Radix Salviae Miltiorrhizae 12 parts, Flos Lonicerae 10 parts, Radix Paeoniae Rubra 9 parts, 12 parts, Poria, the Rhizoma Pinelliae 12 parts, Radix Codonopsis 12 parts, Semen Plantaginis 15 parts, Radix Scrophulariae 12 parts.
Preparation technology is with embodiment 1.
Embodiment 3 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Artemisiae Annuae 11 parts, Cortex Moutan 7 parts, Herba Epimedii 7 parts, Herba Dendrobii 4 parts, Radix Achyranthis Bidentatae 11 parts, Plumula Nelumbinis 11 parts, Caulis Spatholobi 4 parts, Pericarpium Citri Reticulatae 4 parts, Radix Salviae Miltiorrhizae 11 parts, Flos Lonicerae 9 parts, Radix Paeoniae Rubra 8 parts, 11 parts, Poria, the Rhizoma Pinelliae 11 parts, Radix Codonopsis 11 parts, Semen Plantaginis 13 parts, Radix Scrophulariae 10 parts.
Preparation technology is with embodiment 1.
Embodiment 4 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Artemisiae Annuae 10 parts, Cortex Moutan 5 parts, Herba Epimedii 6 parts, Herba Dendrobii 3 parts, Radix Achyranthis Bidentatae 10 parts, Plumula Nelumbinis 10 parts, Caulis Spatholobi 3 parts, Pericarpium Citri Reticulatae 3 parts, Radix Salviae Miltiorrhizae 10 parts, Flos Lonicerae 8 parts, Radix Paeoniae Rubra 6 parts, 10 parts, Poria, the Rhizoma Pinelliae 10 parts, Radix Codonopsis 10 parts, Semen Plantaginis 12 parts, Radix Scrophulariae 9 parts, 5 parts, Radix Glycyrrhizae, Fructus Ligustri Lucidi 13 parts.
Preparation technology is with embodiment 1.
Embodiment 5 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Artemisiae Annuae 12 parts, Cortex Moutan 8 parts, Herba Epimedii 9 parts, Herba Dendrobii 5 parts, Radix Achyranthis Bidentatae 12 parts, Plumula Nelumbinis 12 parts, Caulis Spatholobi 5 parts, Pericarpium Citri Reticulatae 5 parts, Radix Salviae Miltiorrhizae 12 parts, Flos Lonicerae 10 parts, Radix Paeoniae Rubra 9 parts, 12 parts, Poria, the Rhizoma Pinelliae 12 parts, Radix Codonopsis 12 parts, Semen Plantaginis 15 parts, Radix Scrophulariae 12 parts, 8 parts, Radix Glycyrrhizae, Fructus Ligustri Lucidi 12 parts.
Preparation technology is with embodiment 1.
Embodiment 6 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Artemisiae Annuae 11 parts, Cortex Moutan 7 parts, Herba Epimedii 7 parts, Herba Dendrobii 4 parts, Radix Achyranthis Bidentatae 11 parts, Plumula Nelumbinis 11 parts, Caulis Spatholobi 4 parts, Pericarpium Citri Reticulatae 4 parts, Radix Salviae Miltiorrhizae 11 parts, Flos Lonicerae 9 parts, Radix Paeoniae Rubra 8 parts, 11 parts, Poria, the Rhizoma Pinelliae 11 parts, Radix Codonopsis 11 parts, Semen Plantaginis 13 parts, Radix Scrophulariae 10 parts, 6 parts, Radix Glycyrrhizae, Fructus Ligustri Lucidi 15 parts.
Preparation technology is with embodiment 1.
(2) test examples part
Embodiment 7 Chinese medicine composition composition injection is on the impact of systemic lupus erythematosus (sle) MRL/lpr mice
1. experiment material
1.1 laboratory animals and grouping
8 week age, systemic lupus erythematosus (sle) (SLE) MRL/lpr mice 50, female, provided, after adaptability raises one week, be divided into 5 groups at random by body weight by Shanghai Slac Experimental Animal Co., Ltd., often organizes 10.ICR mice 10, female, as Normal group mice.
Normal group: gavage gives solvent;
SLE model group: gavage gives solvent;
Prednisone group: gavage gives 5mg/kg;
Chinese medicine composition low dose group: gavage gives medicine 0.5mg/kg prepared by the embodiment of the present invention 1;
Dosage group in Chinese medicine composition: gavage gives medicine 1mg/kg prepared by the embodiment of the present invention 1;
Chinese medicine composition high dose group: gavage gives medicine 4mg/kg prepared by the embodiment of the present invention 1.
All test group administration every day 1 time, successive administration 3 weeks, gets blood for subsequent use, wins spleen at the end of administration.
1.2 reagent
(1) IL-10, anti-ds-DNA antibody test kit are purchased from Shanghai Ke Feng biological reagent company limited.
(2) PBS: take following reagent 8.5gNaCl, 0.2gKCl, 2.85gNa
2hPO
412H
2o, 0.27gKH
2pO
4, with 1L distilled water standardize solution, above reagent is all be commercially available analytical pure.
(3) erythrocyte cracked liquid: first prepare 0.83%NH
4cl, then prepare tris solution (take tris20.594g to be dissolved in 500-700ml distilled water, then adjust pH7.65 to 1L with 1MHCl), 0.83%NH
4cl and tris solution in 9:1 ratio mixing after and get final product.
(4) anti-mouse fluorescent-tagged mAbs CD3(FITC), be BeckmanCoulter Products.
(5) anti-mouse fluorescent-tagged mAbs CD4(PE), CD8a(PE), Caltaglaboratories product.
Experimental technique
2.1T lymphocyte subgroup is analyzed
The preparation of Single-cell suspensions: the spleen of mice is put into the culture dish filling cold PBS liquid and cleans, 3mlPBS grinding is added in glass homogenizer, filter with 200 order stainless (steel) wires again, centrifugal for Splenic vessel liquid with rotating speed 1500rpm/min centrifugal 7 minutes, abandon supernatant, and add erythrocyte cracked liquid 2.5ml, mixing, leave standstill and after 2 minutes, add PBS liquid 2ml termination lytic response again, with 1500rpm/min centrifugal 7 minutes again, abandoning supernatant, adds PBS after washing three times, under fluorescence microscope, calculate cell number with PBS.Above operation all need on ice.
Use above Single-cell suspensions, after meter cell number, cell concentration is adjusted to 5 × 10
6cells/ml.Each group is got a wherein mouse boosting cell sample and is done subgroup analysis, and the mouse boosting cell sample of adjusted concentration is added flow cytometry dedicated pipe, and two pipes prepared by every mouse boosting cell sample, and often pipe adds sample 100 μ l.
5 μ lCD3(FITC are added at the first pipe containing sample dedicated pipe) and 3 μ lCD4(PE), the second pipe adds 5 μ lCD3(FITC) and 3 μ lCD8(PE).Room temperature black out hatches 20min, and each pipe adds 500 μ l sheath fluids, vibration mixing.Machine analysis in preparation.
2.2 serum IL-10, anti-ds-DNA antibody assay
Operate by test kit operating instruction.
The mensuration of 2.3 microdose urine proteins:
Experiment reagent: 10%(v/v) glacial acetic acid solution (PH2.8); 0.303mol/L glycine-glacial acetic acid buffer (PH3.0): take 22.72g glycine, be diluted to 1000ml with 10% glacial acetic acid solution, add NaN
3100mg, Room-temperature seal Absorbable organic halogens 1 year; Bromophenol blue (1.924mmol/L) stock solution: accurately take 257.36mgBPB, molten to 200ml with dehydrated alcohol, 4 DEG C of refrigerator Absorbable organic halogens 1 year; Bromophenol blue (0.231mmol/L) developer: get 60mlBPB stock solution, add 2.5mlTritonX-100, be diluted to 500ml with glycine-glacial acetic acid buffer, Room-temperature seal can preserve 1 year.
The collection of specimen and detection: in the 20th day mice is put in metabolic cage respectively and raises, collect 12 hours overnight urine, accurate recording urine volume.After sodium azide process, centrifugal (2000r/min) 10min, measures the mice urine 2ml of storage, respectively adds developer 1ml, and mixing (preventing bubble), measures absorbance A with ultraviolet spectrophotometer under 600nm.The content size of absorbance A reflection microdose urine protein, A value is less, and microdose urine protein content is lower.
Experimental data carries out statistical procedures in accordance with the following methods: adopt SPSS10.0 statistical software, and calculate data and represent with mean ± standard deviation (x ± s), many groups data compares employing variance analysis, compares and adopt t inspection in group.With p < 0.05 for there being statistical significance.
Experimental result
3.1 the present invention are on the impact of SLE T lymphocyte subsets in spleen of mice immunized
CD3+CD4+ lymphocyte is helper T lymphocyte (Th), CD3+CD8+ lymphocyte mainly plays inhibition regulating action, SLE mouse model group CD3+CD4+ lymphocyte level is than the decline of Normal group, SLE mouse model group CD3+CD8+ lymphocyte level is than the rising of Normal group, the CD3+CD4+T cell that the present invention can make SLE mice decline rises, the CD3+CD8+T of rising is declined, wherein in Chinese medicine composition, dosage group effect is better, this shows, medicine of the present invention can correct the imbalance state of SLE mouse T cell subgroup.Result of the test is in table 1.
Table 1 the present invention is on the impact of SLE T lymphocyte subsets in spleen of mice immunized
3.2 the present invention are on the impact of serum IL-10, anti-ds-DNA antibody content
Compare with Normal group, IL-10 and the anti-ds-DNA antibody level of SLE model mice obviously raise, compared with SLE model group, the present invention significantly can reduce SLE mice serum IL-10 and anti-ds-DNA antibody level, wherein Chinese medicine composition low, middle dosage group effect is particularly remarkable, be better than positive drug, wherein dosage group and Normal group there was no significant difference in Chinese medicine composition.This shows, medicine of the present invention is remarkable for SLE mice therapeutic effect.Result of the test is in table 2.
Table 2 the present invention is on the impact of SLE mice serum IL-10, anti-ds-DNA antibody content
*compared with Normal group, p < 0.05;
*compared with Normal group, p < 0.01;
#compared with SLE model group, p < 0.05;
##compared with SLE model group, p < 0.01.
3.3 the present invention are on the impact of SLE mouse retention microalbumin content
Microalbuminuria reflection renal abnormality leaky protein, only occur minute quantity albumin in Normal group urine, SLE model group albumin content obviously raises, and reflection SLE mouse kidney has damage; Compared with model group, the present invention significantly can reduce albuminous content in SLE mice urine, and Chinese medicine composition low, middle dosage group effect is particularly remarkable, is better than positive drug, and low, the middle dosage group of Chinese medicine composition and Normal group there was no significant difference.This shows further, and medicine of the present invention has outstanding therapeutic effect for the damage of SLE mouse kidney.Result of the test is in table 3.
Table 3 the present invention on the impact of SLE mouse retention microalbumin content (
)
*compared with Normal group, p<0.05;
*compared with Normal group, p<0.01;
#compared with SLE model group, p<0.05;
##compared with SLE model group, p<0.01.
In the test of t lymphocyte subset cluster analysis, compared with SLE model group, the CD3+CD4+T cell that the present invention can make SLE sample mice decline rises, and the CD3+CD8+T of rising is declined, and corrects the imbalance state of T cell subgroup; In serum IL-10, the test of anti-ds-DNA antibody assay, compared with SLE model group, the present invention significantly can reduce the rising of SLE mice serum IL-10 and anti-ds-DNA antibody level, wherein dosage group and Normal group there was no significant difference in Chinese medicine composition, illustrates that medicine of the present invention is remarkable for SLE mice therapeutic effect; In the determination test of microdose urine protein, SLE model group albumin content obviously raises, reflection SLE mouse kidney has damage, the present invention significantly can reduce albuminous content in SLE mice urine, Chinese medicine composition low, middle dosage group effect is particularly remarkable, be better than positive drug, and low, the middle dosage group of Chinese medicine composition and Normal group there was no significant difference, show that medicine of the present invention has outstanding therapeutic effect for the damage of SLE mouse kidney.
Claims (2)
1. a Chinese medicine composition for systemic lupus erythematosus, is characterized in that being made up of the raw material of following weight portion: Herba Artemisiae Annuae 10 parts, Cortex Moutan 5 parts, Herba Epimedii 6 parts, Herba Dendrobii 3 parts, Radix Achyranthis Bidentatae 10 parts, Plumula Nelumbinis 10 parts, Caulis Spatholobi 3 parts, Pericarpium Citri Reticulatae 3 parts, Radix Salviae Miltiorrhizae 10 parts, Flos Lonicerae 8 parts, Radix Paeoniae Rubra 6 parts, 10 parts, Poria, the Rhizoma Pinelliae 10 parts, Radix Codonopsis 10 parts, Semen Plantaginis 12 parts, Radix Scrophulariae 9 parts;
Described Chinese medicine composition is obtained by following preparation method: get above-mentioned Chinese crude drug and be broken into coarse powder, the alcoholic solution that volumetric concentration is 40% ~ 95% is added according to 4 ~ 9 times of coarse powder gross weight, reflux, extract, three times, return time is 2 ~ 5h, filter, filtrate recycling ethanol, cold filtration, wash with water, after drying, namely obtain Chinese medical concrete; This Chinese medical concrete basis prepares conventional Chinese medicine pharmaceutical dosage form clinically.
2. Chinese medicine composition as claimed in claim 1, is characterized in that: described Chinese medicine composition is powder, water preparation, tablet or capsule.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610020140.4A CN105434894A (en) | 2014-01-02 | 2014-01-02 | Method for preparing traditional Chinese medicine composition for treating systemic lupus erythematosus |
| CN201410000841.2A CN103705754B (en) | 2014-01-02 | 2014-01-02 | A kind of Chinese medicine composition of systemic lupus erythematosus |
| CN201610020138.7A CN105521302A (en) | 2014-01-02 | 2014-01-02 | Applications of traditional Chinese medicinal composition in preparing medicines for treating systemic lupus erythematosus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410000841.2A CN103705754B (en) | 2014-01-02 | 2014-01-02 | A kind of Chinese medicine composition of systemic lupus erythematosus |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610020140.4A Division CN105434894A (en) | 2014-01-02 | 2014-01-02 | Method for preparing traditional Chinese medicine composition for treating systemic lupus erythematosus |
| CN201610020138.7A Division CN105521302A (en) | 2014-01-02 | 2014-01-02 | Applications of traditional Chinese medicinal composition in preparing medicines for treating systemic lupus erythematosus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103705754A CN103705754A (en) | 2014-04-09 |
| CN103705754B true CN103705754B (en) | 2016-03-30 |
Family
ID=50399341
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610020140.4A Withdrawn CN105434894A (en) | 2014-01-02 | 2014-01-02 | Method for preparing traditional Chinese medicine composition for treating systemic lupus erythematosus |
| CN201610020138.7A Withdrawn CN105521302A (en) | 2014-01-02 | 2014-01-02 | Applications of traditional Chinese medicinal composition in preparing medicines for treating systemic lupus erythematosus |
| CN201410000841.2A Active CN103705754B (en) | 2014-01-02 | 2014-01-02 | A kind of Chinese medicine composition of systemic lupus erythematosus |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610020140.4A Withdrawn CN105434894A (en) | 2014-01-02 | 2014-01-02 | Method for preparing traditional Chinese medicine composition for treating systemic lupus erythematosus |
| CN201610020138.7A Withdrawn CN105521302A (en) | 2014-01-02 | 2014-01-02 | Applications of traditional Chinese medicinal composition in preparing medicines for treating systemic lupus erythematosus |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN105434894A (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104547674A (en) * | 2014-12-24 | 2015-04-29 | 广东聚智诚科技有限公司 | New application of traditional Chinese medicinal composition |
| CN104825690A (en) * | 2015-05-30 | 2015-08-12 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating lupus nephritis and application thereof |
| CN104940492A (en) * | 2015-07-27 | 2015-09-30 | 青岛云天生物技术有限公司 | Traditional Chinese medicine composition for treating systemic lupus erythematosus |
| CN105288473A (en) * | 2015-10-30 | 2016-02-03 | 江崇礼 | Traditional Chinese medicine composition for treating lupus erythematosus and application thereof |
| CN106177335A (en) * | 2016-08-24 | 2016-12-07 | 南阳医学高等专科学校 | A kind of pharmaceutical composition of systemic lupus erythematosus and preparation method thereof |
| CN109172724A (en) * | 2018-11-19 | 2019-01-11 | 亳州市君臣佐使药业有限公司 | A kind of Chinese materia medica preparation and preparation method thereof for treating lupus erythematosus |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1048899C (en) * | 1995-04-03 | 2000-02-02 | 刘枝芳 | Lupus powder medicine and its preparation method |
| CN1422643A (en) * | 2001-12-06 | 2003-06-11 | 高大海 | Oral pill for treating lupus erythematosus |
| CN103417531B (en) * | 2012-05-14 | 2016-03-02 | 鲁南制药集团股份有限公司 | The purposes of arctigenin in the medicine preparing systemic lupus erythematosus |
| CN102670831B (en) * | 2012-05-28 | 2014-04-02 | 石家庄平安医院有限公司 | Medicinal composition for treating dermatomyositis and preparation method thereof |
-
2014
- 2014-01-02 CN CN201610020140.4A patent/CN105434894A/en not_active Withdrawn
- 2014-01-02 CN CN201610020138.7A patent/CN105521302A/en not_active Withdrawn
- 2014-01-02 CN CN201410000841.2A patent/CN103705754B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105521302A (en) | 2016-04-27 |
| CN103705754A (en) | 2014-04-09 |
| CN105434894A (en) | 2016-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103705754B (en) | A kind of Chinese medicine composition of systemic lupus erythematosus | |
| CN101310751B (en) | Detection method of medicine composition for replenishing qi and blood | |
| CN105148258A (en) | Composition and application thereof, and preparation containing composition | |
| CN105030562B (en) | A kind of antiallergy complex polysaccharide composition and its preparation method and application | |
| CN108143825B (en) | Medicine for treating psoriasis, preparation method and detection method thereof | |
| CN103417531B (en) | The purposes of arctigenin in the medicine preparing systemic lupus erythematosus | |
| CN104940599A (en) | Application of traditional Chinese medicine composition in preparation of medicines for improving lipid metabolism | |
| CN108714205B (en) | Traditional Chinese medicine granule for treating spleen-kidney yang deficiency type IgA nephropathy and preparation method and application thereof | |
| CN104547514A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus rheumatoid arthritis vasculitis and application thereof | |
| CN102526656A (en) | Medicament or health-care food composition for preventing or/and treating erythremia | |
| CN102652774B (en) | Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method | |
| CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
| CN102846732A (en) | A Chinese medicine composition for the treatment of breast hyperplasia and its preparation method | |
| CN100998687B (en) | Medicine composition for treating chronic gastritis, and its preparing process | |
| CN105477361B (en) | A kind of Chinese medicine composition preparation method that treating gastritis and preparation | |
| CN104547674A (en) | New application of traditional Chinese medicinal composition | |
| CN101081250A (en) | Potygonum multiflorum thunb extract medicament for treating anemia and the preparing method thereof | |
| CN104825690A (en) | Traditional Chinese medicine composition for treating lupus nephritis and application thereof | |
| CN102188592A (en) | Medicine for treating thrombocytopenia after tumor chemotherapy and preparation method thereof | |
| CN104688723A (en) | Application of anhydroicaritin in preparation of medicine for treating anaemia | |
| CN101618157B (en) | Medicine composition for treating autumn-dryness cold and preparation method thereof | |
| CN104208263B (en) | A kind of Chinese medicine composition, preparation method and application | |
| CN104524338B (en) | A kind of Chinese medicine that treating IgA nephrosis and its application | |
| CN115192592B (en) | Application of pulsatilla chinensis saponin composition in preparation of medicines for treating diabetic nephropathy | |
| CN103263467A (en) | Potent medicament of brain-and-heart, preparation method and content determination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhuang Jintian Inventor after: Liu Shupeng Inventor before: Liu Chengxia Inventor before: Zhang Jing |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160303 Address after: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266555, Optics Valley Software Park, second floors Applicant after: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. Applicant after: Zhuang Jintian Applicant after: Liu Shupeng Address before: 266200 Jimo, Qingdao, the Yellow River, No. two, No. Road, building 25, building 182 Applicant before: Wang Xueyan |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160713 Address after: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266555, Optics Valley Software Park, second floors Patentee after: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. Address before: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266555, Optics Valley Software Park, second floors Patentee before: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. Patentee before: Zhuang Jintian Patentee before: Liu Shupeng |
|
| CB03 | Change of inventor or designer information |
Inventor after: Zhuang Jintian Inventor after: Liu Shupeng Inventor after: Wang Yuling Inventor after: Lv Wei Inventor after: Wang Xia Inventor after: Li Ping Inventor before: Zhuang Jintian Inventor before: Liu Shupeng |
|
| CB03 | Change of inventor or designer information | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170525 Address after: 226200 No. 46 Industrial Park, Nanyang Town, Nantong, Jiangsu, Qidong Patentee after: Qidong planting valve factory Address before: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266555, Optics Valley Software Park, second floors Patentee before: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. |